Close Lucintel Chat
Didn't Find What You're Looking for?
Call us at +1972 636 5056 or write at helpdesk@Lucintel.com
Ask an Expert Provide Custom Requirements Download Sample Report Search Available Reports
  • helpdesk@Lucintel.com
  • |
  • Call Lucintel +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
  • Search
  • |
'
...

Request the impact of COVID-19 in this market at no additional cost. Buy it today to get an advantage.

Request Now


The global cardiovascular drugs market sustained modest growth over the past five years and is anticipated to continue the same over 2012-2017 and reach an estimated $174.8 billion by 2017. 

 
Lucintel, a leading global management consulting and market research firm, has analyzed the global cardiovascular drugs industry and offers its findings in its research report, “Global Cardiovascular Drugs market 2012-2017: Trend, Profit, and Forecast Analysis.”
 
The industry is consolidated and affected by government regulations in different regions and countries. The global market is geographically segmented into North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW). During 2006-2011, APAC led the industry in growth and is expected to retain that position through 2017because of economic expansion, increased personal income, improved public healthcare, and longer life expectancies. Currently, North American dominates the industry. China and India are the fastest-growing cardiovascular drugs markets.
 
Lucintel has identified increasing regulatory interference, increasing export barriers, and shift toward lower-price generic drugs as challenges. Increasing healthcare expenditures and awareness, advances in medical technologies, and rising per capita income are industry growth stimulators.
 
Increase in middle class population, changing demographic profile, increase in medical insurance coverage, growing economy, and rising GDP per capita are expected to drive demand for cardiovascular drugs in APAC, providing opportunities to industry players.
 
The report includes manufacturers and distributors of cardiovascular drugs. This market report is an indispensable reference guide for materials suppliers, product manufacturers, investors, executives, distributors, and others that operate in this market. For business, investment, and strategic decisions, the timely, useful information in this market report can help fulfill these core needs. 
 
Lucintel’s research report provides recent industry scope and overview, global macroeconomic overview, relative market attractiveness by region, annual industry trends,

emerging trends, and industry forecasts. In addition, the report presents a Porter's Five Forces Analysis, information about product launches and merger and acquisitions during last five years tha

t determine regional and segment opportunities, competitive landscape, and profitability trend and analysis of major industry players. The key insights sections portray beneficial information about an industry segment's growth and regional growth trends.
 
This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global cardiovascular drugs industry. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.
 
To make any investment or strategic decision, you need adequate and timely information. This market report fulfills this core need. Some of the features of cardiovascular drugs market report are:
 
• Industry size estimates in terms of (US $) value by  regions and by segment
• Global cardiovascular drugs industry annual  trend (2006-2011) and forecast (2012-2017)
• Porter’s Five Force analysis 
• New product launch and merger and acquisition activity in global cardiovascular drugs insurance market
• Quarterly demand trend (Q1 2010-Q4 2011)and forecast analysis (Q1 2012 – Q4 2012) for global cardiovascular drugs market
• Gross and net profit trends in the global cardiovascular drugs market
• Cost structure trend in the global as well as regional global motor cardiovascular drugs market
• More than 45valuable figures/charts and 12 tables are provided in cardiovascular drugs market report
 
 1. Executive Summary  

 2. Industry Definition and Scope  

 3. Industry Overview  

 4. Global Macroeconomic Overview  

 5. Industry Trends  

 6. Industry Forecasts  

 7. Emerging Trends  

 8. Conclusions  

List of Figures
Chapter 3. Industry Overview
Figure3.1 External forces shaping global cardiovascular drugs industry       
                               
Chapter 4. Global Macroeconomic Overview
Figure 4.1: Global GDP growth rate trend          
Figure 4.2: Global inflation rate trend                 
Figure 4.3: Global population growth rate trend  
Figure 4.4: Global unemployment rate trend       
Figure 4.5: Regional GDP growth rate trend       
Figure 4.6: Regional inflation rate trend              
Figure 4.7: Regional population growth rate trend           
Figure 4.8: Regional unemployment rate trend
 
Chapter 5. Industry Trends      
Figure 5.1: Global cardiovascular drugs industry annual trend: 2006-11 ($ B)  
Figure 5.2: Global cardiovascular drugs industry regional trend 2006-11($ B) 
Figure 5.3: Global cardiovascular drugs industry regional trend:  2006-11 (%)
Figure 5.4; Global cardiovascular drugs industry segment trend: 2006-11 ($ B)
Figure 5.5: Global cardiovascular drugs industry segment trend: 2006-11 (%)
Figure 5.6: Global cardiovascular drugs industry quarterly trend:  2006-11 ($ B)
Figure 5.7: Global cardiovascular drugs industry profitability trend:  2006-11
Figure 5.8: Global cardiovascular drugs industry revenue per employee trend: 2006-11
Figure 5.9: Cost structure trend in global cardiovascular drugs industry: 2006-2011
Figure 5.10: Cost Structure Trend in North America cardiovascular drugs industry: 2006-2011
Figure 5.11 Cost structure trend in European cardiovascular drugs industry: 2006-2011
Figure 5.12 Cost structure trend in Asia Pacific cardiovascular drugs industry: 2006-2011
Figure 5.13 Top 5 companies v/s global cardiovascular drugs industry gross profit & net profit analysis 2011
Figure 5.14: Cash on hand for global cardiovascular drugs imaging industry 2006-11($B)
Figure 5.15: Cash on hand for global cardiovascular drugs imaging industry 2006-11(%)
Figure 5.16: Total assets for global cardiovascular drugs imaging industry 2006-11 ($B)
Figure 5.17: Total assets for global cardiovascular drugs imaging industry 2006-11 (%)
Figure 5.18: Total debt for global cardiovascular drugs imaging industry 2006-11 ($ B)
Figure 5.19: Total debt for global cardiovascular drugs imaging industry 2006-11 (%)
Figure 5.20: Industry shares of top players in cardiovascular drugs industry in 2006
Figure 5.21: Industry shares of top players in global cardiovascular drugs industry in 2011
Figure 5.22: Global cardiovascular drugs industry market share analysis 2006
Figure 5.23: Global cardiovascular drugs industry market share analysis 2011
 
Chapter 6. Industry Forecasts
Figure 6.1: Global cardiovascular drugs industry annual forecast 2012-17 ($ B)
Figure 6.2: Global cardiovascular drugs industry quarterly forecast 2012-17 ($ B)
Figure 6.3: Global GDP growth rate forecast                  
Figure 6.4: Global inflation rate forecast
Figure 6.5: Global population growth rate forecast                     
Figure 6.6: Global unemployment rate forecast  
Figure 6.7: Regional GDP growth rate forecast  
Figure 6.8: Regional inflation rate forecast         
Figure 6.9: Regional population growth rate forecast      
Figure 6.10: Regional unemployment rate forecast
Figure 6.11: Global cardiovascular drugs industry regional forecast 2012-2017 ($ B)
Figure 6.12: Global cardiovascular drugs industry regional forecast 2012-2017 (%)
Figure 6.13: Global cardiovascular drugs industry segment forecast 2012-2017 ($ B)
Figure 6.12: Global cardiovascular drugs industry segment forecast 2012-2017 (%)
 
Chapter 7. Emerging Trends    
Figure 7.1: Global cardiovascular drugs industry emerging trend
Figure 7.2: Global cardiovascular drugs industry opportunity by region
Figure 7.3: Global cardiovascular drugs industry opportunity by segment
 
 
 
List of Tables
 
Chapter 3. Industry Overview
Table 3.1: Global cardiovascular drugs industry parameters 2011
Table 3.2: Relative Industry attractiveness by region 
 
Chapter 5. Industry Trends
Table 5.1: Global cardiovascular drugs industry regional growth rate
Table 5.2: Global cardiovascular drugs industry segment growth rate
Table 5.3: Percentage change in cost structure
Table 5.4: Percentage change in cash on hand
Table 5.5: Percentage change in total assets
Table 5.6: Percentage change in total debt
Table 5.7: Key companies by highest revenue growth
Table 5.8: Key companies by lowest revenue growth
 
Chapter 6. Industry Forecasts
Table 6.1: Regional growth rate
Table 6.2: Segment growth rate
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: Cardiovascular Drugs Market: Market Size, Trends and Growth Analysis Full Report $ 1,980
Global Cardiovascular Drugs Industry 2012-2017: Trend, Profit, and Forecast Analysis,July 2012,New
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data 
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
 
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process. 
 

Please sign in below to get report brochure - Cardiovascular Drugs Market.

At Lucintel, we respect your privacy and maintain the confidentiality of information / data provided by you
(Please enter your corporate email. * These fields are mandatory )
Have an Account / Returning Visitors?

Follow us on